Basal Tumours in Bladder Cancer, Response to chemoTherapy

Determine the sensitivity/resistance to chemotherapy of the various subgroups of muscle-invasive bladder cancers, including the basal subgroup (about 25% of these tumours) according to 4 different classifications based on molecular or immunohistochemical classifiers.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bladder Cancer Chemotherapy Effect Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Male Urogenital Diseases Neoplasms Neoplasms by Site Urinary Bladder Diseases Urinary Bladder Neoplasms Urogenital Diseases Urogenital Neoplasms Urologic Diseases Urologic Neoplasms

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

DRCI

Rouen, 76000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

of Patients enrolled in VESPER study:

Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort and :

having signed an informed consent form for the participation to the collection or
dead/lost to follow-up without prior opposition expressed against research program,
genetic analysis will only be carried out for patients who have signed the genetic consent form.

Inclusion criteria

of Patients from St Louis cohort not enrolled in VESPER study:

Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort and :

having received an informed form for the participation to the collection and not having expressed opposition against research program within 1 month or
dead/lost to follow-up without prior opposition expressed against research program,

Exclusion criteria

-Patients enrolled in VESPER study:Tumors from patient having withdrawn his/her informed consent form for the participation to the collection and/or VESPER project.

-Patients from St Louis not enrolled in VESPER study:Tumors from patient having expressed opposition against research program after 1 month for the participation to the collection.

Treatment and study plan

neoadjuvant chemotherapy with cisplatine

Combination Product

Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine

Primary outcomes

Identifying molecular subgroups of bladder cancer patients within VESPER and Saint-Louis cohort, who could benefit from neoadjuvant chemotherapy, taking into account the existence of different classification systems.

Time frame: through study completion, an average of 3 years
Determining which classification(s) has(ve) the best ability to identifying subgroups of tumours sensitive or resistant to neoadjuvant chemotherapy.

Time frame: through study completion, an average of 3 years
Identifying mechanisms of resistance in basal subgroups.

Time frame: through study completion, an average of 3 years

Sponsors and collaborators

Lead sponsor

University Hospital, Rouen

Other

Collaborators

APHP
Institut Curie

Registry information

Acronym: BoBCaT

Important dates

Study start: 2019
Primary completion: 2019
Study completion: 2019
First posted: Sep 13, 2019
Registry last updated: Jun 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed